Sotaro Enatsu

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 613 citations · Full text

Medicine, Oncology, Pharmacology +12

SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK

Yutaka Okawa, Teru Hideshima, Paul M. Steed et al. · Blood · 2008 · 209 citations · Full text

Medicine, Oncology, Pharmacology +16

Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations

Ying Cheng, Haruyasu Murakami, Pan‐Chyr Yang et al. · Journal of Clinical Oncology · 2016 · 187 citations

Medicine, Oncology, Pharmacotherapy +14

A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy

Kiyotaka Yoh, Yukio Hosomi, Kazuo Kasahara et al. · Lung Cancer · 2016 · 112 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Overexpression of IQGAP1 in advanced colorectal cancer correlates with poor prognosis—critical role in tumor invasion

Hiroyuki Hayashi, Kazuki Nabeshima, Mikiko Aoki et al. · International Journal of Cancer · 2009 · 65 citations

Medicine, Oncology, Pathology +17